Review

Nature Reviews Cancer 6, 107-116 (February 2006) | doi:10.1038/nrc1799

Focus on: Biomarkers

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

Stephen B. Baylin1 & Joyce E. Ohm1  About the authors

Top

Chromatin alterations have been associated with all stages of tumour formation and progression. The best characterized are epigenetically mediated transcriptional-silencing events that are associated with increases in DNA methylation — particularly at promoter regions of genes that regulate important cell functions. Recent evidence indicates that epigenetic changes might 'addict' cancer cells to altered signal-transduction pathways during the early stages of tumour development. Dependence on these pathways for cell proliferation or survival allows them to acquire genetic mutations in the same pathways, providing the cell with selective advantages that promote tumour progression. Strategies to reverse epigenetic gene silencing might therefore be useful in cancer prevention and therapy.

Author affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting–Blaustein Cancer Research Building, 1650 Orleans Street, Suite 530, Baltimore, Maryland 21231, USA.
    Email: sbaylin@JHMI.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

CIMPle origin for promoter hypermethylation in colorectal cancer?

Nature Genetics News and Views (01 Jul 2006)

A bird's eye view of global methylation

Nature Genetics News and Views (01 Feb 2000)

Extra navigation

Subscribe

Subscribe to Nature Reviews Cancer

Search PubMed for

naturejobs

natureproducts


Advertisement